drugset / Trial / NCT01935804

Effect of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes

NCT01935804

Phase 2 Completed 440 enrolled King Abdulaziz University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study tests whether pioglitazone (PIO)as compared to metformin (MET)affects bone health including bone mineral density, bone turnover markers, and osteocyte biomarker in patients with type 2 diabetes (T2DM).

Timeline

Start
2009-01
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 850 mg Oral
Subject Pioglitazone Small molecule 30 mg Oral